Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19060201 | SINGLE-STRANDED END PRESERVING ADAPTORS | February 2025 | March 2026 | Allow | 13 | 2 | 1 | Yes | No |
| 17929420 | CHARACTERIZATION AND LOCALIZATION OF PROTEIN MODIFICATIONS | September 2022 | December 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17816215 | METHODS OF GENE ASSEMBLY USING DNAZYMES AND USE IN DNA DATA STORAGE | July 2022 | February 2026 | Allow | 43 | 3 | 1 | Yes | No |
| 17732932 | BIOLOGICAL SAMPLE CAPTURE WITH MULTIPLEX ANALYSIS | April 2022 | June 2025 | Allow | 38 | 2 | 0 | No | No |
| 17733888 | UNIVERSAL ADAPTOR FOR SEQUENCING | April 2022 | February 2026 | Abandon | 45 | 3 | 0 | No | No |
| 17772117 | METHOD OF PRODUCING BIOCHIPS | April 2022 | January 2026 | Allow | 45 | 2 | 0 | No | No |
| 17642849 | RECOMBINANT TRANSPOSON ENDS | March 2022 | February 2026 | Abandon | 47 | 0 | 1 | No | No |
| 17676720 | MULTIPLEXED ENGINEERED CELLS AND SYSTEMS FOR BIOFUEL PRODUCTION | February 2022 | January 2026 | Abandon | 47 | 1 | 0 | No | No |
| 17624497 | NOVEL APPROACH FOR INCREASING CONTRACTILITY IN PATIENTS WITH SYSTOLIC HEART FAILURE | January 2022 | January 2026 | Abandon | 49 | 1 | 0 | No | No |
| 17617070 | DNA METHYLATION BASED HIGH RESOLUTION CHARACTERIZATION OF MICROBIOME USING NANOPORE SEQUENCING | December 2021 | March 2026 | Abandon | 51 | 1 | 0 | No | No |
| 17543476 | METHODS FOR MAPPING PERSONALIZED TRANSLATOME | December 2021 | July 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17538594 | METHOD AND SYSTEM FOR DETECTING MTDNA MUTATIONS | November 2021 | February 2026 | Allow | 50 | 1 | 0 | No | No |
| 17615311 | Method for Creating a cDNA Sequencing Library | November 2021 | November 2025 | Allow | 47 | 2 | 0 | No | No |
| 17456353 | Systems and Methods to Assess RNA Stability | November 2021 | October 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17509988 | POLYNUCLEOTIDE MODIFICATION METHODS | October 2021 | January 2026 | Allow | 51 | 1 | 0 | Yes | No |
| 17490549 | DNA METHYLATION SEQUENCING ANALYSIS METHODS | September 2021 | January 2026 | Abandon | 51 | 1 | 0 | No | No |
| 17600339 | INTESTINAL BIOMARKERS FOR GUT HEALTH IN DOMESTICATED BIRDS | September 2021 | November 2025 | Abandon | 50 | 1 | 0 | No | No |
| 17593811 | METHOD FOR IDENTIFYING FUNCTIONAL ELEMENTS | September 2021 | November 2025 | Abandon | 50 | 0 | 1 | No | No |
| 17284734 | METHOD FOR CONSTRUCTING SEQUENCING LIBRARY | September 2021 | October 2025 | Abandon | 55 | 1 | 0 | No | No |
| 17438571 | Compartment-Free Single Cell Genetic Analysis | September 2021 | August 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17473173 | Methods of Selecting and Detecting Binding Peptides | September 2021 | February 2026 | Abandon | 53 | 2 | 0 | No | No |
| 17438217 | Methods for Single Cell Intracellular Capture and its Applications | September 2021 | January 2026 | Abandon | 52 | 1 | 1 | No | No |
| 17466790 | DNA METHYLTRANSFERASE 1 TRANSITION STATE STRUCTURE AND USES THEREOF | September 2021 | November 2025 | Abandon | 50 | 0 | 1 | No | No |
| 17436398 | COMPOSITIONS AND METHODS OF TARGETED NUCLEIC ACID ENRICHMENT BY LOOP ADAPTER PROTECTION AND EXONUCLEASE DIGESTION | September 2021 | September 2025 | Allow | 48 | 2 | 0 | No | No |
| 17434251 | COMPOSITIONS AND METHODS FOR ENHANCING MUCOSAL IMMUNITY | August 2021 | September 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17430530 | HAPLOTAGGING - HAPLOTYPE PHASING AND SINGLE-TUBE COMBINATORIAL BARCODING OF NUCLEIC ACID MOLECULES USING BEAD-IMMOBILIZED TN5 TRANSPOSASE | August 2021 | February 2026 | Allow | 54 | 2 | 1 | No | No |
| 17429250 | PRODUCTION AND TRACKING OF ENGINEERED CELLS WITH COMBINATORIAL GENETIC MODIFICATIONS | August 2021 | January 2026 | Allow | 53 | 1 | 1 | No | No |
| 17427576 | METHOD OF SEQUENCING NUCLEIC ACID WITH UNNATURAL BASE PAIRS | July 2021 | August 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17443909 | COMBINATORIAL SETS OF NUCLEIC ACID BARCODES FOR ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS | July 2021 | July 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17369425 | Microfluidic Devices and Methods for Use Thereof in Multicellular Assays of Secretion | July 2021 | December 2025 | Abandon | 53 | 2 | 0 | Yes | No |
| 17421175 | METHODS AND KITS FOR GENERATING AND SELECTING A VARIANT OF A BINDING PROTEIN WITH INCREASED BINDING AFFINITY AND/OR SPECIFICITY | July 2021 | October 2025 | Abandon | 51 | 1 | 0 | No | No |
| 17416287 | IDENTIFICATION OF COGNATE PAIRS OF LIGANDS AND RECEPTORS | June 2021 | December 2025 | Allow | 54 | 2 | 0 | No | No |
| 17312238 | GENERATING SPATIAL ARRAYS WITH GRADIENTS | June 2021 | November 2025 | Abandon | 54 | 1 | 1 | No | No |
| 17299323 | ROLLING CIRCLE AMPLIFICATION METHOD, METHOD FOR PREPARING SEQUENCING LIBRARY, AND DNA NANOSPHERE PREPARED THEREFROM | June 2021 | August 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17243931 | METHODS OF DRUG SCREENING USING DNA BARCODING | April 2021 | February 2026 | Abandon | 57 | 1 | 0 | No | No |
| 17284098 | METHODS AND REAGENTS FOR ANALYSING NUCLEIC ACIDS FROM SINGLE CELLS | April 2021 | February 2026 | Abandon | 58 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner LAFAVE, ELIZABETH ROSE works in Art Unit 1684 and has examined 27 patent applications in our dataset. With an allowance rate of 33.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner LAFAVE, ELIZABETH ROSE's allowance rate of 33.3% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LAFAVE, ELIZABETH ROSE receive 1.11 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LAFAVE, ELIZABETH ROSE is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +48.9% benefit to allowance rate for applications examined by LAFAVE, ELIZABETH ROSE. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.